Beta-glucans supplementation associates with reduction in P-cresyl sulfate levels and improved endothelial vascular reactivity in healthy individuals

PLoS ONE

Volumn 12, Issue 1, 2017, Pages

  Cosola, Carmela ^a   De Angelis, Maria ^a   Rocchetti, Maria Teresa ^a   Montemurno, Eustacchio ^a   Maranzano, Valentina ^a   Dalfino, Giuseppe ^a   Manno, Carlo ^a   Zito, Annapaola ^a   Gesualdo, Michele ^a   Ciccone, Marco Matteo ^a   Gobbetti, Marco ^b   Gesualdo, Loreto ^a  

^a UNIVERSITY OF BARI   (Italy)

^b FREE UNIVERSITY OF BOZEN BOLZANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCAN; CHOLESTEROL; INDICAN; LOW DENSITY LIPOPROTEIN; PARA CRESYL SULFATE; UNCLASSIFIED DRUG; UREMIC TOXIN; 4-CRESOL SULFATE; CRESOL; SULFATE;

ADULT; ARTICLE; BARLEY; BLOOD VESSEL FUNCTION; BLOOD VESSEL REACTIVITY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIET SUPPLEMENTATION; FEMALE; FLOW MEDIATED DILATION; HUMAN; HUMAN EXPERIMENT; INTERVENTION STUDY; INTESTINE FLORA; LIPOPROTEIN BLOOD LEVEL; MALE; MICROBIAL METABOLISM; NONHUMAN; NORMAL HUMAN; PASTA; PILOT STUDY; PROTEIN DEGRADATION; THERAPY EFFECT; VASCULAR ENDOTHELIUM; BLOOD; DIET; DRUG EFFECTS; ELECTROSPRAY MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; METABOLISM; PHYSIOLOGY; TANDEM MASS SPECTROMETRY;

ADULT; BETA-GLUCANS; CHOLESTEROL; CHROMATOGRAPHY, LIQUID; CRESOLS; DIET; ENDOTHELIUM, VASCULAR; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SULFURIC ACID ESTERS; TANDEM MASS SPECTROMETRY;

EID: 85010402862     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0169635     Document Type: Article

References (47)

1. Purchiaroni F, Tortora A, Gabrielli M, Bertucci F, Gigante G, Ianiro G et al. The role of intestinal micro-biota and the immune system. Eur Rev Med Pharmacol Sci 2013; 17(3): 323-333 PMID: 23426535
2. Guinane CM, Cotter PD. Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. Therap Adv Gastroenterol. 2013; 6(4): 295-308 doi: 10.1177/1756283X13482996 PMID: 23814609
3. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444(7122): 1027-1031 doi: 1038/nature05414 PMID: 17183312
4. De Angelis M, Montemurno E, Piccolo M, Vannini L, Lauriero G, Maranzano V et al. Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN). PLoS One. 2014; 12; 9(6): e99006 doi: 10.1371/journal.pone.0099006 PMID: 24922509
5. Delzenne NM, Cani PD, Everard A, Neyrinck AM, Bindels LB. Gut microorganisms as promising targets for the management of type 2 diabetes. Diabetologia. 2015; 58(10): 2206-2217 doi: 10.1007/s00125-015-3712-7 PMID: 26224102
6. Piccolo M, De Angelis M, Lauriero G, Montemurno E, Di Cagno R, Gesualdo L et al. Salivary Microbiota Associated with Immunoglobulin A Nephropathy. Microb Ecol 2015; 70(2): 557-565 doi: 10.1007/s00248-015-0592-9 PMID: 25763757
7. Sun J, Chang EB. Exploring gut microbes in human health and disease: Pushing the envelope. Genes Dis 2014; 1(2): 132-139 doi: 10.1016/j.gendis.2014.08.001 PMID: 25642449
8. Flint HJ, Scott KP, Duncan SH, Louis P, Forano E. Microbial degradation of complex carbohydrates in the gut. Gut Microbes. 2012; 3(4): 289-306 doi: 10.4161/gmic.19897 PMID: 22572875
9. Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI. Human nutrition, the gut microbiome, and immune system: envisioning the future. Nature 2011; 474(7351): 327-336
10. Leonel AJ, Alvarez-Leite JI. Butyrate: implications for intestinal function. Curr Opin Clin Nutr Metab Care. 2012; 15(5): 474-479 doi: 10.1097/MCO.0b013e32835665fa PMID: 22797568
11. Puertollano E, Kolida S, Yaqoob P. Biological significance of short-chain fatty acid metabolism by the intestinal microbiome. Curr Opin Clin Nutr Metab Care 2014; 17(2): 139-144 doi: 10.1097/MCO.0000000000000025 PMID: 24389673
12. Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. Adv Immunol 2014; 121: 91-119 doi: 10.1016/B978-0-12-800100-4.00003-9 PMID: 24388214
13. Vipperla K, O'Keefe SJ. The Microbiota and Its Metabolites in Colonic Mucosal Health and Cancer Risk. Nutr Clin Pract 2012; 27: 624-635 doi: 10.1177/0884533612452012 PMID: 22868282
14. Viaene L, Annaert P, de Loor H, Poesen R, Evenepoel P, Meijers B. Albumin is the main plasma binding protein for indoxyl sulfate and p-cresyl sulfate Biopharm. Drug Dispos 2013; 34: 165-175
15. Ito S, Yoshida M. Protein-Bound Uremic Toxins: New Culprits of Cardiovascular Events in Chronic Kidney Disease Patients. Toxins. 2014; 6: 665-678 doi: 10.3390/toxins6020665 PMID: 24561478
16. Gerritsen J, Smidt H, Rijkers GT, de Vos WM Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr. 2011; 6(3): 209-240 doi: 10.1007/s12263-011-0229-7 PMID: 21617937
17. Candela M, Biagi E, Maccaferri S, Turroni S, Brigidi P. Intestinal microbiota is a plastic factor responding to environmental changes. Trends Microbiol. 2012; 20(8): 385-391 doi: 10.1016/j.tim.2012.05.003 PMID: 22672911
18. Montemurno E, Cosola C, Dalfino G, Daidone G, De Angelis M, Gobbetti M et al. What would you like to eat, mr CKD microbiota? A Mediterranean diet, please! Kidney Blood Press Res 2014; 39: 114-123 doi: 10.1159/000355785 PMID: 25117687
19. Andersson KE, Hellstrand P. Dietary oats and modulation of atherogenic pathways. Mol Nutr Food Res. 2012; 56: 1003-1013 doi: 10.1002/mnfr.201100706 PMID: 22764134
20. FDA 21 CFR 101.81 62 Health claims: Soluble fiber from certain foods and risk of coronary heart disease (CHD); FR 3600, Jan. 23, 1997
21. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to beta-glucans and maintenance of normal blood cholesterol concentrations (ID 754, 755, 757, 801,1465,2934) and maintenance or achievement of a normal body weight (ID 820, 823) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 on request from the European Commission. EFSA Journal. 2009; 7(9): 1254
22. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to beta-glucans from oats and barley and maintenance of normal blood LDL-cholesterol concentrations (ID 1236,1299), increase in satiety leading to a reduction in energy intake (ID 851, 852), reduction of post-prandial glycaemic responses (ID 821, 824), and "digestive function" (ID 850) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal. 2011; 9(6): 2207
23. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to barley beta-glucans and lowering of blood cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006. EFSA Journal. 2011; 9(12): 2471
24. Nilsson AC, Östman EM, Erik Bach Knudsen K, Holst JJ, Björck IME. A Cereal-Based Evening Meal Rich in Indigestible Carbohydrates Increases Plasma Butyrate the Next Morning. J Nutr 2010; 140(11): 1932-1936 doi: 10.3945/jn.110.123604 PMID: 20810606
25. De Angelis M, Montemurno E, Vannini L, Cosola C, Cavallo N, Gozzi G et al. Effect of whole-grain barley on human fecal microbiota and metabolome. Appl Environ Microbiol. 2015; 81(22): 7945-7956 doi: 10.1128/AEM.02507-15 PMID: 26386056
26. Katz DL, Nawaz H, Boukhalil J, Giannamore V, Chan W, Ahmadi R et al. Acute Effects of Oats and Vitamin E on Endothelial Responses to Ingested Fat. Am J Prev Med 2001; 20(2): 124-129 PMID: 11165454
27. Momenizadeh A, Heidari R, Sadeghi M, Tabesh F, Ekramzadeh M, Haghighatian Z et al. Effects of oat and wheat bread consumption on lipid profile, blood sugar, and endothelial function in hypercholesterol-emic patients: A randomized controlled clinical trial. ARYA Atheroscler 2014; 10(5): 259-265 PMID: 25477983
28. Tabesh F, Sanei H, Jahangiri M, Momenizadeh A, Tabesh E, Pourmohammadi K et al. The effects of beta-glucan rich oat bread on serum nitric oxide and vascular endothelial function in patients with hypercholesterolemia. Biomed Res Int 2014; 2014: 481904 doi: 10.1155/2014/481904 PMID: 25025057
29. Martinez-Gonzalez Miguel Angel, Garcia-Arellano Ana, Toledo Estefania, Salas-Salvado Jordi, Buil-Cosiales Pilar, Corella Dolores et al. A 14-Item Mediterranean Diet Assessment Tool and Obesity Indexes among High-Risk Subjects: The PREDIMED Trial. PLoS One. 2012; 7(8): e43134 doi: 10.1371/journal.pone.0043134 PMID: 22905215
30. Itoh Y, Ezawa A, Kikuchi K, Tsuruta Y, Niwa T. Protein bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal Bioanal Chem. 2012; 403: 1841-1850. doi: 10.1007/s00216-012-5929-3 PMID: 22447217
31. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002; 39: 257-265 PMID: 11788217
32. Ciccone MM, Iacoviello M, Puzzovivo A, Scicchitano P, Monitillo F, De Crescenzo F et al. Clinical correlates of endothelial function in chronic heart failure. Clin Res Cardiol. 2011; 100(6): 515-521 doi: 10.1007/s00392-010-0275-y PMID: 21212968
33. Wu IW, Hsu KH, Lee CC Sun CY, Hsu HJ, Tsai CJ et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 2011; 26(3), 938-947 doi: 10.1093/ndt/gfq580 PMID: 20884620
34. Rossi M, Johnson DW, Morrison M, Pascoe EM, Coombes JS, Forbes JM et al. Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY). A Randomized Trial. Clin J Am Soc Nephrol 2016; 11(2): 223-231 doi: 10.2215/CJN.05240515 PMID: 26772193
35. Nakabayashi I, Nakamura M, Kawakami K, Ohta T, Kato I, Uchida K et al. Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study. Nephrol Dial Transplant 2011; 26(3): 1094-1098 doi: 10.1093/ndt/gfq624 PMID: 20929916
36. Ciccone MM, Miniello V, Marchioli R, Scicchitano P, Cortese F, Palumbo V et al. Morphological and functional vascular changes induced by childhood obesity. Eur J Cardiovasc Prev Rehabil. 2011; 18(6): 831-835 doi: 10.1177/1741826711398180 PMID: 21450599
37. Ciccone MM, Cortese F, Gesualdo M, Carbonara S, Zito A, Ricci G et al. Dietary intake of carotenoids and their antioxidant and anti-inflammatory effects in cardiovascular care. Mediators Inflamm. 2013; 2013: 782137 doi: 10.1155/2013/782137 PMID: 24489447
38. Witte DR, Westerink J, de Koning EJ, van der Graaf Y, Grobbee DE, Bots ML. Is the association between flow-mediated dilation and cardiovascular risk limited to low-risk populations? J Am Coll Cardiol. 2005 21; 45(12): 1987-1993 doi: 10.1016/j.jacc.2005.02.073 PMID: 15963397
39. Wang CP, Lu LF, Yu TH, Hung WC, Chiu CA, Chung FM et al. Associations among chronic kidney disease, high total p-cresylsulfate and major adverse cardiac events. J Nephrol 2013; 26(1): 111-118
40. Tang WH, Wang CP, Yu TH, Hung WC, Chung FM, Lu YC et al. Serum total p-cresyl sulfate level is associated with abnormal QTc interval in stable angina patients with early stage of renal failure. Clin Chim Acta 2014; 437: 25-30 doi: 10.1016/j.cca.2014.07.002 PMID: 25011013
41. Vanholder R, Schepers E, Pletinck A, Nagler EV, Glorieux G. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol 2014; 25(9): 1897-1907 doi: 10.1681/ASN.2013101062 PMID: 24812165
42. Rossi M, Campbell K, Johnson D, Stanton T, Pascoe E, Hawley C et al. Uraemic toxins and cardiovascular disease across the chronic kidney disease spectrum: an observational study. Nutr Metab Cardiovasc Dis 2014; 24(9): 1035-1042 doi: 10.1016/j.numecd.2014.04.006 PMID: 24880738
43. Meijers BKI, Evenepoel P. The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrol Dial Transplant 2011; 26: 759-761 doi: 10.1093/ndt/gfq818 PMID: 21343587
44. Massy ZA, Barreto DV, Barreto FC et al. Uraemic toxins for consideration by the cardiologist-beyond traditional and non-traditional cardiovascular risk factors. Atherosclerosis 2010; 211: 381-383 doi: 10.1016/j.atherosclerosis.2010.04.010 PMID: 20471651
45. Lin CJ, Wu V, Wu PC, Wu CJ. Meta-Analysis of the Associations of p-Cresyl Sulfate (PCS) and Indoxyl Sulfate (IS) with Cardiovascular Events and All-Cause Mortality in Patients with Chronic Renal Failure. PlosOne 2015, 10(7): e0132589
46. Nakajima K, Nakano T, Tokita Y, Nagamine T, Inazu A, Kobayashi J et al. Postprandial lipoprotein metabolism: VLDL vs chylomicrons. Clin Chim Acta 2011; 15-412(15-16): 1306-1318
47. Norata GD, Grigore L, Raselli S, Redaelli L, Hamsten A, Maggi F et al. Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis 2007; 193(2): 321-327 doi: 10.1016/j.atherosclerosis.2006.09.015 PMID: 17055512